Drugs / GenSci161
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07476586 | Apr 2026 → May 2027 expected | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Changchun GeneScience Pharmaceutical Co., Ltd. | Regulatory GenSci's Innovative IL-1α/β Bispecific Antibody Receives First FDA Clinical Approval genscigroup.com ↗
Recently, GenSci161 Injection, a fully human bispecific antibody, has obtained FDA approval to initiate clinical trials in the United States for hidradenitis suppurativa (HS), marking its first FDA-approved clinical indication in the country. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci's Innovative IL-1α/β Bispecific Antibody Receives First FDA Clinical Approval genscigroup.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07476586 ↗ |
| Route | Subcutaneous | “Administered subcutaneous injection” NCT07476586 ↗ |